Can-Fite BioPharma Ltd. (CANF) stock
CANFNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.56+0.14 (+9.86%)
Close on Nov 16, 2026Market cap $2.04MP/E –Yield –
Can-Fite BioPharma price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Can-Fite BioPharma's price to sales ratio was 8.2× on Nov 11, 2026, against 6.9× a year earlier. Over the last 5 years it ranged from 3.9× to 42.1×, with a median of 13.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 8.2× | +4.3 |
| 2025 | Dec 31, 2025 | 3.9× | −8.3 |
| 2024 | Dec 31, 2024 | 12.2× | +1.1 |
| 2023 | Dec 29, 2023 | 11.1× | −8.5 |
| 2022 | Dec 30, 2022 | 19.5× | −9.5 |
| 2021 | Dec 31, 2021 | 29.1× | +17.1 |
| 2020 | Dec 31, 2020 | 12.0× | +10.9 |
| 2019 | Dec 31, 2019 | 1.1× | −24.8 |
| 2018 | Dec 31, 2018 | 26.0× | −98.2 |
| 2017 | Dec 29, 2017 | 124.2× | +124.0 |
| 2016 | Dec 30, 2016 | 0.2× | – |
See a number that looks wrong?